Publications

Maity D, Sivakumar N, Kamat P, Zamponi N, Min C, Du W, Jayatilaka H, Johnston A, Starich B, Agrawal A et al..  2024.  Profiling Dynamic Patterns of Single-Cell Motility.. Adv Sci (Weinh). :e2400918.

Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.

Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E et al..  2022.  Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.. Blood. 139(8):1147-1159.

Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, N Henry L, Dillon H, Little RF et al..  2022.  A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas . J Geriatr Oncol. 13(2):258-264.

Zaitsev A, Chelushkin M, Dyikanov D, Cheremushkin I, Shpak B, Nomie K, Zyrin V, Nuzhdina E, Lozinsky Y, Zotova A et al..  2022.  Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes.. Cancer Cell. 40(8):879-894.e16.

Cerchietti L, Pera B.  2015.  Personalized Epigenetic Therapy - Chemosensitivity Testing. Epigenetic Cancer Therapy. :667-676.

Goldstein RL, Yang SNing, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G et al..  2015.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.. J Clin Invest. 125(12):4559-71.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ.  2014.  Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.

Cerchietti LC, Yang SNing, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.  2009.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.. Blood. 113(15):3397-405.

Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.

Cerchietti LCA, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BMC.  2005.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.. J Neurooncol. 71(1):73-81.

Cerchietti LCA, Navigante AH, Körte MW, Cohen AM, Quiroga PN, Villaamil EC, Bonomi MR, Roth BM.  2003.  Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study.. Pain. 105(1-2):265-73.